Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Muncie, IN
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Muncie, IN
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Metairie, LA
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Minneapolis, MN
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
St. Louis, MO
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Las Vegas, NV
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Hickory, NC
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Middletown, OH
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Middletown, OH
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Bend, OR
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  6/1/2016
mi
from
Buenos Aires,
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 6/1/2016
mi
from
Buenos Aires,
Click here to add this to my saved trials
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens
Status: Enrolling
Updated:  6/8/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens
Status: Enrolling
Updated: 6/8/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens
Status: Enrolling
Updated:  6/8/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens
Status: Enrolling
Updated: 6/8/2016
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Aurora, CO
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Washington,
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Lebanon, NH
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Portland, OR
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Pleasant Hill, CA
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
San Diego, CA
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Port St. Lucie, FL
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Port St. Lucie, FL
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Decatur, IL
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Decatur, IL
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Southfield, MI
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Southfield, MI
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Lake Success, NY
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Spokane, WA
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
Clinical Research Facility
mi
from
Madison, WI
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  6/22/2016
mi
from
Herston,
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 6/22/2016
mi
from
Herston,
Click here to add this to my saved trials
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
Status: Enrolling
Updated:  6/23/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
Status: Enrolling
Updated: 6/23/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Veterans Affairs Medical Center - Birmingham
mi
from
Birmingham, AL
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Veterans Affairs Medical Center - Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Huntsville Hospital System
mi
from
Huntsville, AL
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Huntsville Hospital System
mi
from
Huntsville, AL
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Urology Associates - Mobile AL
mi
from
Mobile, AL
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Urology Associates - Mobile AL
mi
from
Mobile, AL
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
MBCCOP - University of South Alabama
mi
from
Mobile, AL
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
MBCCOP - University of South Alabama
mi
from
Mobile, AL
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Alabama Oncology, LLC
mi
from
Montgomery, AL
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Alabama Oncology, LLC
mi
from
Montgomery, AL
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Radiation Oncology Associates of West Alabama
mi
from
Tuscallosa, AL
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Radiation Oncology Associates of West Alabama
mi
from
Tuscallosa, AL
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Providence Cancer Therapy Center
mi
from
Anchorage, AK
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Providence Cancer Therapy Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Arizona Cancer Center
mi
from
Tucson, AZ
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Providence Saint Joseph Medical Center - Burbank
mi
from
Burbank, CA
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Mount Diablo Medical Center
mi
from
Concord, CA
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Mount Diablo Medical Center
mi
from
Concord, CA
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Beckman Research Institute, City of Hope
mi
from
Duarte, CA
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Beckman Research Institute, City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
California Cancer Center
mi
from
Fresno, CA
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
California Cancer Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Saint Agnes Cancer Center
mi
from
Fresno, CA
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Saint Agnes Cancer Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Glendale Memorial Hospital and Health Center
mi
from
Glendale, CA
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Glendale Memorial Hospital and Health Center
mi
from
Glendale, CA
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Sutter Health Western Division Cancer Research Group
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated:  6/27/2016
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Talc in Treating Patients With Malignant Pleural Effusion
Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study
Status: Enrolling
Updated: 6/27/2016
Veterans Affairs Medical Center - Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials